Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Nature(2005)10.1038/nature03445Source: DataRank Database

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy is a research paper published in Nature (2005). On theSindex it has a DataRank of 1.3. It has been cited 6,630 times.

N/A

1.3DataRank · unranked

Scored on demand from live citation data

6,630 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 52.61)OA: closedTopics (55)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

1.3

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (16)

Nuala McCabe,Christopher J. Lord ORCID,Damian A. Johnson,Tobias B. Richardson,Manuela Santarosa ORCID

Live enrichment

PubMed:15829967 OpenAlex:https://openalex.org/W1973268287

Breast Cancer Now

Grant: BREAST CANCER NOW RESEARCH CENTRE

NCI NIH HHS

Grant: F31 CA260794

Wellcome Trust

Grant: unidentified

unidentified

FWCI

52.61

Citation Percentile

1.0%

Influential Citations

239

Citation Trend

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

closedLicense: Springer TDM

publisherhttp://www.nature.com/articles/nature03445.pdf

publisherhttp://www.nature.com/articles/nature03445

journalhttps://doi.org/10.1038/nature03445

repositoryhttps://pubmed.ncbi.nlm.nih.gov/15829967

repositoryhttps://www.nature.com/articles/nature03445

Fields of Study

DNA Repair MechanismsPARP inhibition in cancer therapyCRISPR and Genetic EngineeringBiologyMedicine0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsAnimalsAntineoplastic AgentsCell SurvivalDNA DamageDNA RepairMice, NudeModels, BiologicalMutationNeoplasmsPoly(ADP-ribose) PolymerasesSubstrate SpecificityApoptosisGenes, BRCA1Xenograft Model Antitumor AssaysGenes, BRCA2Mice

Keywords

Homologous recombinationDNA repairPoly ADP ribose polymeraseGenome instabilityDNA damageBiologyBase excision repairPolymeraseDNA repair protein XRCC4DNACancer researchNucleotide excision repairCell biologyGenetics570Cell SurvivalGenes, BRCA2Genes, BRCA1Mice, NudeAntineoplastic AgentsApoptosisPoly(ADP-ribose) Polymerase InhibitorsModels, BiologicalXenograft Model Antitumor AssaysSubstrate SpecificityMiceNeoplasmsMutationAnimalsPoly(ADP-ribose) Polymerases

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

10.6084/m9.figshare.25466600.v1figshare

Additional file 1 of A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

10.6084/m9.figshare.25466600figshare

Additional file 1 of Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

10.6084/m9.figshare.11978706.v1figshare

Additional file 1 of Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

10.6084/m9.figshare.11978706figshare

Additional file 3 of Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

10.6084/m9.figshare.11978715.v1figshare

Additional file 3 of Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer

10.6084/m9.figshare.11978715figshare

Additional file 1 of ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer

10.6084/m9.figshare.12154017.v1figshare

10.6084/m9.figshare.12154017figshare

Additional file 1 of Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

10.6084/m9.figshare.12421322.v1figshare

Additional file 1 of Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

10.6084/m9.figshare.12421322figshare

Additional file 2 of Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

10.6084/m9.figshare.12421328.v1figshare

Additional file 2 of Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

10.6084/m9.figshare.12421328figshare

Additional file 1 of Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

10.6084/m9.figshare.14196636.v1figshare

Additional file 1 of Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells

10.6084/m9.figshare.14196636figshare

Additional file 2 of Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

10.6084/m9.figshare.14391492.v1figshare

Additional file 2 of Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

10.6084/m9.figshare.14391492figshare

Additional file 1 of Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

10.6084/m9.figshare.14433107.v1figshare

Additional file 1 of Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

10.6084/m9.figshare.14433107figshare

Additional file of Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

10.6084/m9.figshare.14433110.v1figshare

Additional file of Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

10.6084/m9.figshare.14433110figshare